Prof. Dr. Antonio Pezzutto

Medical Degrees

• Graduation — MBBS, University of Padova Medical School, Italy, 1972
• Post Graduation — Specialty Training in Internal Medicine and Hematology/Oncology, University of Heidelberg, Germany, 1983

Fellowships & Special Training

• Resident — University of Padova Medical School, Italy
• Resident — University of Heidelberg, Germany
• Specialty Training in Hematology, Oncology, and Tumour Immunology — University of Heidelberg

Certifications & Accreditations

• Berlin Medical Council Registration
• Specialist (Facharzt) Certification — Internal Medicine, Hematology, and Oncology, Germany
• Full Professor — Charité Berlin

Major Conditions Treated

• Acute Leukaemias (AML, ALL)
• Chronic Leukaemias (CML, CLL)
• Hodgkin's Lymphoma
• Non-Hodgkin's Lymphoma (NHL)
• Peripheral T-Cell Lymphoma
• B-Cell Non-Hodgkin Lymphomas (with MYD88 Mutations)
• Multiple Myeloma
• Bleeding Disorders
• Blood Clots / Thrombotic Disorders
• Stem Cell Transplant Indications
• Solid Tumours (Medical Oncology)

Sub-specialties

• Stem Cell Transplantation: Specialist in autologous, allogenic, and umbilical cord blood stem cell transplantation — a leading hematologist specialist in Berlin for transplant-eligible blood cancer patients.
• Lymphoma & Tumour Immunology: Co-investigator on landmark trials (ECHELON-2, ACT-1) and research on MYD88 mutations in B-cell NHLs — among the best hematologist doctor in Germany for advanced lymphoma immunotherapy.
• Tumour Immunology & TCR Therapy: Past Medigene clinical TCR (T-cell receptor) study leader, contributing to next-generation immunotherapy.

Advanced Procedures & Treatments

• Autologous Stem Cell Transplantation
• Allogenic Stem Cell Transplantation
• Umbilical Cord Blood Transplantation
• Chemotherapy (Multi-Agent Regimens)
• Targeted Therapy (Tyrosine Kinase Inhibitors, Monoclonal Antibodies)
• Immunotherapy / Checkpoint Inhibitors
• T-Cell Receptor (TCR) Therapy
• Bone Marrow Aspiration & Biopsy
• Lymphoma Treatment Protocols (R-CHOP, ABVD, Brentuximab Vedotin)
• Leukaemia Induction & Consolidation Therapy
• Bleeding Disorder Management

Current Affiliation

• Charité — Universitätsmedizin Berlin, Campus Benjamin Franklin (CBF), Germany — Director, Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie (Present)
• Charité Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin — Affiliated Faculty (Concurrent)
• Max-Delbrück-Centrum für Molekulare Medizin (MDC), Robert-Rössle-Straße 10, 13125 Berlin, Germany — Affiliated Researcher (Concurrent)

Past Affiliations

• Medigene AG — Clinical TCR (T-Cell Receptor) Study Leader (Past)
• University of Heidelberg, Germany — Specialty Training in Internal Medicine and Hematology/Oncology, 1983
• University of Heidelberg, Germany — Resident
• University of Padova Medical School, Italy — Resident and Medical Studies, completed 1972

Academic & Research Roles

• Full Professor — Charité Berlin
• Co-author — "Taschenatlas der Immunologie" with Burmester, Thieme
• Co-author — "Color Atlas of Immunology", Thieme
• Active researcher — MYD88 mutations in B-cell non-Hodgkin lymphomas
• Co-investigator — ECHELON-2 trial (Brentuximab Vedotin in peripheral T-cell lymphoma)
• Co-investigator — ACT-1 trial
• Past Medigene Clinical TCR Study Leader

Key Achievements

• 42+ years of distinguished experience in hematology, oncology, and tumour immunology
• 265+ peer-reviewed publications
• 7,023+ citations across the body of work
• Co-author of leading immunology textbooks (Thieme)

National & International Awards

• Full Professorship — Charité Berlin
• Co-authorship of internationally translated immunology textbooks (Thieme)

Professional Memberships

• German Society for Hematology and Medical Oncology (DGHO)
• European Society for Medical Oncology (ESMO)
• American Society of Hematology (ASH)
• American Society of Clinical Oncology (ASCO)
• European Hematology Association (EHA)
• Berlin Medical Council

Published Papers (Selected)

• 265+ peer-reviewed scientific publications across hematology, oncology, and tumour immunology — accessible via PubMed.
• 7,023+ citations across the body of work.
• Burmester GR, Pezzutto A. Color Atlas of Immunology. Thieme.
• Burmester GR, Pezzutto A. Taschenatlas der Immunologie. Thieme.
• Co-investigator: ECHELON-2 Trial (Brentuximab Vedotin in peripheral T-cell lymphoma).
• Co-investigator: ACT-1 Trial.

Ongoing Research & Clinical Interests

• Stem cell transplantation outcomes
• MYD88 mutations in B-cell non-Hodgkin lymphomas
• Peripheral T-cell lymphoma (ECHELON-2)
• T-Cell Receptor (TCR) therapy and tumour immunology

*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.